Gilead Sciences Inc. began a Phase III trial of its PI3K inhibitor, GS-1101, in chronic lymphocytic leukemia (CLL). If successful, the company could add a cancer candidate to its powerhouse lineup of products currently led by its HIV and hepatitis C virus franchises.